Potential infectious etiologies of atherosclerosis: a multifactorial perspective. by O'Connor, S. et al.
Synopses
Emerging Infectious Diseases 780 Vol. 7, No. 5, September-October 2001
Potential Infectious Etiologies of Atherosclerosis: 
A Multifactorial Perspective
Siobhán O’Connor,* Christopher Taylor,† Lee Ann Campbell,‡ Stephen Epstein,§ 
and Peter Libby¶
*Centers for Disease Control and Prevention, Atlanta, GA, USA; †National Institute for Allergy and 
Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA; ‡University of 
Washington, Seattle, Washington, USA; §MedStar Research Institute, Washington Hospital Center, 
Washington, DC, USA; and  ¶Brigham and Women’s Hospital, Harvard Medical School, Boston, 
Massachusetts, USA
Coronary heart disease (CHD) contributes substantially to illness and death
worldwide. Experimental studies demonstrate that infection can stimulate
atherogenic processes. This review presents a spectrum of data regarding the
link between CHD and infection. In addition, the need for improved diagnostic
tools, the significance of multiple pathogens, and potential intervention strate-
gies are discussed.
Cardiovascular disease (CVD) from all causes accounts
for 29% of deaths worldwide and ranks second only to infec-
tious and parasitic diseases (1). Deaths from CVD are often
premature, and millions of nonfatal events result in disabil-
ity. Atherosclerosis, a major component of CVD, has properly
been considered a public health problem of industrialized
countries, accounting for an estimated one third of deaths
overall (1). In the United States alone, atherosclerosis
reportedly affects one in four persons, causing approximately
42% of all deaths. Approximately half of these are due to ath-
erosclerotic coronary heart disease (CHD) (2-4). Atheroscle-
rotic CVD now threatens developing countries as well,
perhaps reflecting greater exposure to certain risk factors
with rising standards of living (5). In India, for example,
higher socioeconomic status correlates with increases in risk
factors for and rates of CVD (5). Thus, the need for public
health measures to limit its impact is expanding worldwide. 
Many persons with atherosclerosis, however, lack identi-
fiable traditional risk factors. The well-recognized influences
of smoking, diet and exercise, hypercholesterolemia, hyper-
tension, diabetes, and some genetic factors account for much
less than 100% of disease. Despite continued reductions in
the prevalence of modifiable risk factors, the steady, two-
decade decrease in cardiovascular mortality rates in western
industrialized countries has reached a plateau (2-4). In con-
trast with India, death rates for chronic (including athero-
sclerotic) and infectious diseases in the United States are
inversely related to education and income (4-6). These obser-
vations fuel renewed interest in a link between atheroscle-
rotic CVD and as-yet poorly defined environmental
exposures, including infectious agents. If epidemiologic and
laboratory evidence eventually supports the association, ath-
erosclerosis could emerge as another noncommunicable
chronic condition related to infection.
How strong is the link? This review examines several
candidate infectious agents, referring to reports and reviews
by investigators summarizing their own work and a body of
research. It discusses the potential roles of less well-estab-
lished factors, interactions between infection and traditional
risk factors, and unanswered questions on etiology, patho-
genesis, and appropriate interventions. Developing an
appropriate research agenda and public health response
requires clarification of these issues. The following discus-
sion provides a foundation for future studies.
Infection as an Inflammatory Stimulus
Atherogenic processes resemble many aspects of chronic
inflammation (7), a response that may be promoted by micro-
organisms (8-10). Accordingly, reviews have revisited the
venerable hypothesis of an infectious etiology (8,9,11).
Experimental animal studies have shown that bacterial and
viral agents could contribute to atherogenesis. Both Chlamy-
dia pneumoniae and cytomegalovirus (CMV), for example,
are widely distributed, can infect blood vessel wall cells, and
exhibit persistence, latency, and recurrence of infection.
However, the potential mechanisms of infection-induced ath-
erosclerosis remain speculative.
The earliest lesions of atherogenesis consist of arterial
intimal accumulations of foam cells (primarily lipid-laden
macrophages) and T lymphocytes intermixed with smooth
muscle cells (7). Infection could indirectly influence this pro-
cess without infiltrating the artery wall (Figure 1). Host
defenses to extravascular infections usually elicit proinflam-
matory cytokines and stimulate increased expression of cel-
lular adhesion molecules, enhancing leukocyte adhesion.
These cytokines could elicit a second wave or “echo” from
inflammatory cells already at sites of atherogenesis, such as
arterial wall cells or macrophages (12). Circulating microbial
products such as endotoxin can also produce an echo. Simi-
larly, cytokines induced by extravascular infection (specifi-
cally interleukin-6) characteristically elicit hepatic synthesis
of acute-phase reactants, some of which might promote
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atheromata complicated by thrombosis. Accordingly, levels of
the acute-phase reactant fibrinogen correlate prospectively
with risk for coronary events, and plasminogen activator
inhibitor can promote clot stability by interfering with fibrin-
olysis (7-10). Still, direct infection of the arterial wall could
promote evolution of atherosclerotic lesions or precipitate
acute cardiovascular events. These potential effects are dis-
cussed below.
Chlamydia pneumoniae Association
Lines of evidence associating C. pneumoniae with ath-
erosclerosis include seroepidemiologic studies, direct detec-
tion of bacterial components in atherosclerotic lesions,
occasional isolation of viable organisms from coronary and
carotid atheromatous tissue, and in vitro and animal experi-
ments (reviewed in 8,9,13,14). Most cross-sectional and pro-
spective studies have correlated seroprevalence with
myocardial infarction, chronic CHD, or stroke (8,13,15).
However, the diagnostic criteria used, cut-off titers to define
seropositivity, adjustment for confounders (e.g., smoking),
and sample sizes have varied notably. Indeed, as the interre-
lationships of smoking,  C. pneumoniae  infection, socioeco-
nomic status, and atherosclerotic CVD are further
investigated, epidemiologists continue to discuss which data
adjustments are most appropriate (16-19). Interpretation of
these studies is complicated by a lack of standardized sero-
logic methods and by interlaboratory variations and poor
reproducibility in microimmunofluorescence test results (20-
22). Temporal variations in antibody and antigen titers and
the high prevalence of infection–more than 50% of adults
have been infected at least once–also complicate interpreta-
tion (13). Still, more than 38 studies have reported a positive
association between antibodies to C. pneumoniae and athero-
sclerotic disease. Only four studies did not confirm this asso-
ciation, including two recent, large, well-controlled
investigations in which anti-C. pneumoniae immunoglobulin
(Ig) G titers did not correlate prospectively with risk for coro-
nary events in men or women (18,23-25). Additionally, the
prospective Atherosclerosis Risk in Communities Study cor-
related IgG titers >1:64 with incident CHD, but the relation-
ship did not persist after the data were adjusted for several
cardiovascular risk factors (26).
The strongest evidence associating C. pneumoniae with
atherosclerotic CVD has been detection of bacterial compo-
nents in atherosclerotic lesions. C. pneumoniae appears to
have a tropism for atheromata. It is rarely found in normal
arteries or infectious and noninfectious granulomas and is
documented more frequently in atheromata than in lung or
other tissue from the same patient (13). Over 30 peer-
reviewed publications from investigators worldwide, using
different diagnostic methods, have localized  C. pneumoniae
antigen, DNA, or both in atheromata; three reports did not
find such components (8,27,28). Although detection rates
have varied depending on the diagnostic methods used, the
cumulative evidence supports existence of the organism in
many lesions (8,27). These histologic findings, however, do
not establish a causal role for C. pneumoniae in atherogene-
sis. Despite improved yields, culture of C. pneumoniae from
atheromata remains difficult (8,13,29). Moreover, while the
presence of a viable microbe or its components at a site sug-
gests that it may initiate or exacerbate disease, it does not
prove pathogenesis.
Detection of C. pneumoniae antigens or DNA in intimal
thickening and fatty streaks of young adults and Alaskan
Natives (the latter group at low risk for coronary atheroscle-
rosis) supports an early microbial role in pathogenesis (30).
Postmortem, the Alaskan retrospective study also positively
correlated prior systemic infection with evidence of C. pneu-
moniae in atherosclerotic lesions; studies from Seattle
reported a slightly higher detection rate in late-stage lesions
(13). Recently, investigators reported a statistically signifi-
cant relationship between the presence of  C. pneumoniae
and the severity of human coronary atherosclerosis (31).
Although others observed no correlation between C. pneumo-
niae and disease severity in the same coronary artery, evi-
dence of the bacterium was found in 80% of patients’ arteries
examined (32).
Detection of  C. pneumoniae in plaques has not corre-
lated well with serology (8,33), so investigators have
attempted to predict endovascular infection through poly-
merase chain reaction (PCR) detection of microbial DNA in
peripheral blood monocytes.  The prevalence of C. pneumo-
niae DNA in these mononuclear cells has varied between
studies (perhaps due to differences in both assay sensitivity
and extraction procedures), but was 59% in coronary angiog-
raphy patients compared with 44% in blood donors in one
series; the rate appears to increase with age (33,34). Several
but not all investigators have now correlated PCR-positive
mononuclear cells with clinical CHD (34,35) or the detection
of C. pneumoniae nucleic acid in atherosclerotic aortic tissue
(36).
In vitro studies support hypotheses that C. pneumoniae
might directly promote atherosclerosis (Figure 2). Infection
of human endothelial cells augments their production of
inflammatory cytokines and modulates expression of adhe-
sion molecules, enhancing recruitment of inflammatory leu-
kocytes to the vessel wall (8,37,38). Chlamydial endotoxins,
much less virulent than those of enterobacteriaceae (e.g.,
Escherichia coli), can promote macrophage foam cell forma-
tion in vitro (8,39). Furthermore, C. pneumoniae heat shock
Figure 1. “Echo” hypothesis: activation of atheroma-associated cells by bacte-
rial products and cytokines released in response to extravascular infection. a.
Extravascular infection stimulates production of inflammatory cytokines, e.g.
interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-"), that can elicit an
echo cytokine response from inflammatory cells in residence at sites of athero-
genesis. Circulating microbial products, e.g. endotoxin, can also elicit an echo
response at the artery wall. b. Extravascular infection-elicited cytokines stimu-
late hepatic synthesis of acute-phase reactants. Some factors, e.g. fibrinogen,
might influence complicated atheromata formation or arterial thrombosis.Synopses
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protein (HSP-60) can activate both macrophage tumor necro-
sis factor-alpha and expression of matrix-degrading protein-
ases that may weaken atherosclerotic plaques, rendering
them susceptible to rupture and hence thrombosis. HSP-60
can induce proinflammatory activities in macrophages and
vascular cells (e.g., endothelium, smooth muscle cells) and
promote oxidation of lipoproteins by macrophages (10,40).
Animal experiments have also explored the link between
C. pneumoniae and atherosclerosis. Intranasal or intratra-
cheal C. pneumoniae inoculation of New Zealand white rab-
bits fed a normal diet produced inflammatory changes of the
aorta (41-43). Although one group did not observe foam cells
in inflamed sites, another has reported foam cells in lesions
resembling early atherosclerosis. Macrolide antibiotic ther-
apy appeared to dampen the additive effects of hypercholes-
terolemia and serial  C. pneumoniae infection (9,41,43);
macrolide antibiotics with antichlamydial activity adminis-
tered early in infection could prevent changes, but delayed
treatment had little or no effect (41). These observations,
along with diminished effects on cholesterol-induced lesions
(in the absence of infection), suggest antimicrobial mecha-
nisms of action.
Inflammatory changes without foam cell lesions and
typical atheromata have also been observed in  C. pneumo-
niae-infected mice fed a normal chow diet (13,44). However,
C. pneumoniae infection does potentiate the atherogenic
effects of hypercholesterolemia in three mouse models. Intra-
nasal inoculation of apolipoprotein E-deficient mice fed a
regular chow diet accelerated aortic arch plaque develop-
ment (45); similar changes occurred in low-density lipid
receptor-deficient mice on a high-cholesterol regime but not
those on a regular diet (46). In C57BL/6J mice fed a high-fat,
high-cholesterol diet, C. pneumoniae infection accelerated
the development of atherosclerotic lesions in the aortic sinus
(44,47). 
Although experimental animal lesions do not mimic
human atherogenesis exactly, similarities have prompted
human intervention studies directed against C. pneumoniae
infection. Three prospective therapeutic trials have been
reported, but all had insufficient statistical power to resolve
the question (reviewed in 23,48). One described a fivefold
decrease in cardiovascular events among seropositive men
treated with short courses of azithromycin after myocardial
infarction (MI) (49). In a double-blind study of unstable
angina or non-Q wave infarction, patients treated for 30 days
with roxithromycin had a decrease in cardiovascular events
that waned by 6 months (50). Additionally, when 302 MI sur-
vivors with  C. pneumoniae antibody titers >1:16 were
treated for 3 months with azithromycin, investigators
observed no significant reduction in recurrent events at 6
and 24 months, although a gradual decline in serologic
(inflammatory) markers of cardiovascular risk was initially
seen (51,52). Three disparate retrospective, multivariate
analyses of antibiotic use and CHD risk, using different
methods and populations, also reported both positive and
negative correlations between past antibiotic prescriptions
and CHD or MI risk (48). At this time, any specific effects of
treatment remain unclear (23).
Cytomegalovirus Links
Almost two decades ago, several investigators suggested
a role for herpesviruses in CVD. Lesions resembling human
atheromata developed in pathogen-free chickens infected
with Marek disease virus, an avian herpesvirus; immuniza-
tion with turkey herpesvirus was protective. In vitro,
infected arterial smooth muscle cells accumulated choles-
terol. Since then, seroepidemiologic, histopathologic, in vitro,
and animal studies have investigated possible links between
human atherosclerosis and human herpesviruses, primarily
CMV (reviewed in 14,15,53-55). 
Studies have linked CMV to three arterial diseases: pri-
mary atherosclerosis, post-angioplasty restenosis, and post-
transplantation arteriosclerosis. For each, seroepidemiology
has relied on single measures of viral IgG antibodies, which
only indicate previous exposure. Similar to C. pneumoniae,
the worldwide ubiquity of lifelong, latent CMV infections,
Figure 2. Possible direct effects of Chlamydia pneumoniae (Cpn) on atheromata. Cpn infection augments endothelial cell production of inflam-
matory cytokines and expression of adhesion molecules, e.g., vascular cell adhesion molecule (VCAM)-1, enhancing leukocyte recruitment to
the arterial wall. Chlamydial endotoxin (LPS) may promote macrophage foam cell formation at the site. Chlamydial heat shock protein (HSP-
60) may elicit proinflammatory functions from arterial wall macrophages, endothelium, and smooth muscle cells (SMC), or promote macrop-
hage oxidation of lipoproteins.Synopses
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temporal variations in antibody or antigen titers, and viral
reactivation could mask or falsely highlight causality. These
factors may explain inconsistencies in cross-sectional, retro-
spective, and prospective studies attempting to correlate
seroprevalence or higher IgG titer with primary atheroscle-
rosis (10,14,15,24,56-58). Differing disease classifications
(based on histopathology of vascular surgery, general
autopsy or atherectomy specimens, angiography, noninva-
sive carotid imaging, or clinical history) and epidemiologic
methods (small sample sizes, diminished statistical signifi-
cance after data adjustment, nonuniform consideration of
other risk factors) also limit interpretation (14,53,55).
Results are conflicting even in prospective, nested case-con-
trol investigations focused on but not limited to male Cauca-
sians. The Atherosclerosis Risk in Communities Study
correlated preexisting high anti-CMV titers and traditional
risk factors with carotid atherosclerosis, incident MI or CHD
death (relative risk 1.76; 95% confidence interval 1.00-3.11)
during a 5-year follow-up period (57). In contrast, the 12-
year Physician’s Health Study found no association between
antibody prevalence and subsequent first MI or thromboem-
bolic stroke, or elevated C-reactive protein (56), while the
Cardiovascular Health Study correlated antibodies to herpes
simplex virus type 1 but not CMV or C. pneumoniae with
incident events in the elderly (59).
In post-angioplasty restenosis, preexisting and high-
titer IgG CMV antibodies predicted restenosis (43% vs. 8%)
independently of CVD risk factors, but the sample size was
small and no follow-up titer analysis was included
(53,60,61). Cross-sectional and prospective studies also link
CMV to post-transplant arteriosclerosis (14,62-64), in which
a subset of immunosuppressed recipients manifests acceler-
ated disease in the first year.
Evidence of CMV in these disease entities, however, does
not prove causality. Different techniques have detected viral
antigens and nucleic acids in 0% to 94% of plaques (mean
40%-50%, usually localized to the periphery of advanced
plaques), but also in most of the uninvolved arteries from the
same patients and >50% of random arterial specimens
(14,54,65). A recent PCR analysis of coronary arteries and
venous bypass graft occlusions found no CMV in specimens
but did detect  C. pneumoniae (66). Reports of viral nucleic
acids in post-transplantation arteriosclerotic lesions, using
different techniques, are not uniform (62,63,67,68).
In vitro observations support a potential etiologic role
for CMV in atherosclerotic CVD. Indirectly, virally provoked
paracrine expression of chemokines and growth factors
might stimulate migration of smooth muscle cells from the
adventitia and media into the intima, along with smooth
muscle cell proliferation, both important components of
atherogenesis and restenosis (54). Direct infection of arterial
smooth muscle cells appears to augment expression of the
CMV chemokine receptor US28 (69). Investigators have also
reported inhibited apoptosis and augmented cellular prolif-
eration when the virally directed protein IE2-84 binds or
inhibits transcriptional activity of p53 (54,70). Direct CMV
infection may also enhance uptake of oxidized low-density
lipoprotein by macrophages and smooth muscle cells, pro-
moting foam cell development; through its immediate-early
gene products, CMV may increase uptake of modified low-
density lipoprotein and stimulate type A scavenger receptor
gene expression by smooth muscle cells (54).
CMV animal experiments also do not duplicate human
disease but can provide insight on causality. While CMV
infection of rats several months preceding or during balloon
injury to the carotid artery augmented neointimal thicken-
ing (54,71), infection 14 days after injury did not (72). In
ApoE-deficient mice, systemic infection was reported to
increase atherosclerotic lesion size (54); local infection accen-
tuated subendothelial inflammation and coronary arterio-
sclerosis in rat cardiac and aortic allografts, apparently
reduced by ganciclovir (DHPG) treatment (55,73). Thus,
CMV remains potentially linked to the promotion of athero-
sclerotic CVD.
Roles for Other Microbes?
Oral Pathogens
During the past decade, several reports have suggested
a relationship between chronic oral infections (e.g., periodon-
titis) and cardiovascular disease (74). Among the Pima Indi-
ans, periodontitis emerged as an independent risk factor for
atherosclerotic events (74). Other studies described an asso-
ciation between tooth loss related to periodontal disease and
CVD (75), while persons with diabetes have a higher inci-
dence of infections (including oral) and atherosclerotic CVD.
Pathogens potentially associated with CVD include Porphy-
romonas gingivalis, Bacteroides forsythus, Campylobacter
rectus, Fusobacterium nucleatum, Treponema spp., and Pre-
votella species. At least two, P. gingivalis (42%) and Strepto-
coccus sanguis (12%), were identified in the periphery of
atherosclerotic plaques by immunologic stain (65). Another
group detected  >2 periodontal pathogens by PCR for
16SrDNA in 13 of 22 endarterectomy specimens (76). 
Researchers have hypothesized that certain persons
with a hyperinflammatory phenotype are at increased risk
for both periodontitis and atherosclerotic CVD, with dietary
and other factors possibly altering disease progression
(reviewed in 74). Like  C. pneumoniae, oral bacteria might
affect atherosclerosis through direct invasion of vascular
endothelial cells or indirectly through products that stimu-
late proinflammatory and prothrombotic functions of vascu-
lar cells. For example, P. gingivalis and  S. sanguis both
express a platelet-aggregation factor (74). However, the true
links between oral bacteria and atherosclerotis are still to be
determined, requiring further laboratory and carefully
adjusted clinical studies.
Helicobacter pylori, Herpes Simplex Virus (HSV), 
and Other Pathogens
The literature linking H. pylori, HSV-1, and HSV-2 to
atherogenesis is less extensive than for  C. pneumoniae or
CMV (9,14,15,25,53,59). H. pylori has not been detected in
human atheromata, and available seroepidemiologic data
conflict, weakening the proposed etiologic association
(9,14,15,25). Social factors linked to CVD and H. pylori infec-
tion, including socioeconomic status, may confound these
reported associations, and data were not adjusted appropri-
ately in most studies (15,77). Nonetheless, an indirect role
for H. pylori in the pathogenesis of atherosclerosis has not
been disproved. 
Unlike CMV, HSV-1 has a predilection for epithelial and
neuronal tissues, not mononuclear cells. Seroepidemiologic
and histopathologic study results vary widely (53,55-57,59).Synopses
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For example, the prospective, nested Atherosclerosis Risk in
Communities Study found no association between incident
CHD and preexisting HSV-1 antibodies (57). Although con-
sistent with most other analyses (25,53,56), this contrasts
with positive HSV-1 results from the elderly Cardiovascular
Health Study cohort (59).
In summary, laboratory investigations suggest but do
not conclude that herpesviridae could directly and indirectly
induce several endothelial cell responses involved in athero-
thrombosis (78). The long-term effects of commonly silent or
chronic herpesvirus or other persistent infections render
plausible a potential role in atherosclerotic CVD.
Key Issues for Future Research on Potential 
Infectious Etiologies of CVD
Chronic diseases, including atherosclerosis, have com-
plex causal mechanisms. Accepting the infection hypothesis
for atherosclerotic CVD depends on several key issues,
including those discussed below.
Concept of Multiple Pathogens
Long-term exposure to proinflammatory, toxic, or trans-
forming microbes and their products is a possible mechanism
for infection-related atherosclerotic CVD, as is exposure to
the aggregate effects of coinfections, detected or undetected.
Screening for C. pneumoniae, CMV, and HSV-1, one group of
investigators detected 2-3 microbes in 32% of atherosclerotic
lesions, mostly in plaque shoulders and inflammatory infil-
trates; 71% of the organisms identified were C. pneumoniae.
Expanding the analysis, this group reported a range of 1-4
microbes in atheromata, including the oral pathogens P. gin-
givalis and S. sanguis (65). These findings do not confirm
pathogenesis, but do highlight the possibility of synergy
between organisms or a cumulative infectious effect in
atherogenesis. As emphasized at a 1998 National Institutes
of Health workshop, research on associations between infec-
tion and atherosclerotic CVD must consider the coinfluence
of multiple infectious agents (79).
Investigators are testing the hypothesis of dose-
response relationships between atherosclerotic CVD and the
number of microbes to which a person has been exposed (54).
For example, a recent prospective cohort related expression
of antibodies against several pathogens to MI or death in
patients with angiographically documented coronary artery
disease (80). Perhaps cardiovascular risk increases with
cumulative or earlier exposure to more or specific microbes
(potentially atherogenic). C. pneumoniae infection of cells in
vitro may activate a reporter gene controlled by the CMV
major immediate-early promoter (81). In vivo co-infection
might reactivate latent CMV infection, increase the activity
of persistent virus, or both.
Integration of Infection into a Multifactorial 
View of CHD Risk
Infection as a potential CVD risk factor requires consid-
eration in context. Although interventions targeting tradi-
tional risk factors have often reduced clinical disease,
considerable impact persists. Perhaps microbes enhance the
harmful effects of traditional causes; for example, foam cells
in dyslipedemia-induced lesions might respond to bacterial
inflammatory products. Genetic and gender predispositions
could determine an association between periodontitis and
atherosclerosis (74). Physical activity, smoking, and lipids
could modulate immune status and thus individual suscepti-
bility to acute, reactivated, or persistent infections that are
potentially important in atherogenesis (4,22,79). 
Gender and nutrition can each influence immune
responses to infection and atherothrombotic disease. Sup-
porting sex determination of atherosclerotic CVD, the Patho-
logical Determinants of Atherosclerosis in Youth study found
more extensive fatty streaks in the right coronary arteries
and thoracic aortas of men, but greater abdominal aortic dis-
ease in women (82). Among primates, which have diet-
induced atheromata resembling those of humans, premeno-
pausal female monkeys develop less atherosclerosis than
males (83); females with low levels of social stress developed
the least disease, stressed males the most. Could gender
affect susceptibility to or immune response following athero-
genesis-inducing infection? Reports that sex steroid hor-
mones (e.g., estrogen) can modulate endothelial cell
production of microbial-induced proinflammatory factors
such as cytokines, endothelin-1, angiotensin II, and nitric
oxide suggest a single common pathway (84). 
Nutritional effects on atherosclerosis also extend beyond
hypercholesterolemia, hypertriglyceridemia, and obesity.
Years of rigorous investigation have linked antioxidant con-
sumption to coronary artery disease, and the antioxidant
vitamin E suppresses viral infection (85). However, results of
antioxidant vitamin supplementation on reduction of athero-
sclerotic risk have generally proven disappointing (85,86).
Nevertheless, if nutrition affects inflammatory response to
potentially atherogenic infections, adjunct therapies could
exploit nutritional supplementation in high-risk popula-
tions.
Methods Limit Conclusions
Clarification of the above issues requires improved ana-
lytic tools. Current reagents and methods are not sufficient
to prove or refute a potential infectious etiology in athero-
sclerotic CVD. Public health officials, laboratory investiga-
tors, and clinicians participating in two 1998 workshops
emphasized that deficiencies in these tools weaken conclu-
sions (22,79). As an example, culturing C. pneumoniae from
clinical specimens is difficult, and serology has relied on
tedious, reagent- and reader-dependent microimmunofluo-
rescence; immunocytochemistry and PCR substrates and
techniques vary between laboratories. Temporal fluctuations
in bacteremia or viremia can alter PCR analysis of periph-
eral blood monocytes, and no assay yet differentiates the
presence of any microbe from its role in pathogenesis. Study
comparability and reproducibility will require standardized,
sensitive, and specific reagents (20-22). 
Adding to the ambiguity, human studies have focused on
late-stage atherothrombotic disease, while animal studies
have concentrated on earlier stages of atherogenesis (i.e., ini-
tiation). These issues are critical for translating experimen-
tal evidence to human disease because childhood exposures
to ubiquitous infections are common, frequencies of reexpo-
sure are unknown, and the age at which microbes might
influence atherosclerosis is uncertain. Additionally, available
analytic tools do not characterize the roles of past, active,
persistent latent, or recurrent infection. Recommendations
from a recent international workshop sponsored by the Cen-
ters for Disease Control and Prevention and the LaboratorySynopses
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Centre for Disease Control (Canada) seek to improve the
reproducibility and comparability of C. pneumoniae investi-
gations (20,21). In the future, more sensitive and specific
assays, including microarray technologies (e.g., pathogen-
specific identification chip) may also enhance specimen anal-
ysis (21).
Antimicrobial Therapy: Potential Benefits and Risks
If evidence substantiates a link between infection and
atherosclerotic CVD, targeted antimicrobial therapy might
mitigate atherosclerosis in persons at risk; controlling infec-
tions might decrease the impact of disease. Inappropriate
antimicrobial therapy, however, could accelerate develop-
ment of resistance in both associated and nontargeted organ-
isms, without changing disease outcomes. Studies linking
level of antibiotic use and prevalence of resistant bacteria in
hospitals and communities justify these concerns; trends
toward more frequent erythromycin- and penicillin-resistant
pneumococci with higher antibiotic consumption reversed
when macrolide use was reduced (87-89). 
Although clinical antibiotic resistance in C. pneumoniae
has not been described, certain characteristics–its some-
times asymptomatic, chronic, or recurrent nature–may favor
this development (87). Indeed, laboratories have described
antibiotic-resistant strains of  C. trachomatis, a closely
related organism. Antimicrobial delivery to intracellular C.
pneumoniae is not well described, efficacy during different
stages of the life cycle (e.g., infectious elementary bodies,
replicative reticulate bodies) is unclear (8,87), and antibody
titers do not reliably track infection (87). Whether antibiotics
can eradicate or suppress C. pneumoniae replication, partic-
ularly in the persistent or latent state, remains conjectural.
Clinically, azithromycin resistance in any  Chlamydia spp.
has not been extensively evaluated; however, a transient,
rebound increase in resistant pneumococci has been
observed following single-dose therapy for trachoma (90),
and increased carriage of macrolide-resistant microbes has
accompanied macrolide therapy for otitis media (91).
Widespread or long-term antibiotic use in atheroscle-
rotic CVD could adversely affect beneficial commensals that
provide nutrients and inhibit pathogen overcolonization, as
well as increase antimicrobial resistance in unrelated
microbes. Similar issues may emerge with antiviral therapies. 
Vaccines
If antibiotics or antiviral agents do not limit the patho-
genesis of acute, latent, or chronic active infections, vaccines
are an alternative approach to prevention or treatment. For
example, anti-Chlamydia vaccines have been sought for
decades. Recent advances in immunologic techniques and
description of the complete C. pneumoniae genomic sequence
permit identification of antigens that may elicit protective
immunity (92,93). However, poor understanding of host
defense mechanisms still impedes the development and
application of C. pneumoniae and other microbial vaccines.
The essential components of humoral and cell-mediated
immune responses associated with protection must be iden-
tified before prophylactic vaccine trials against any pathogen
are implemented. To minimize the risk of stimulating
autoimmunity, concerns for cross-reactivity during immuni-
zation must be addressed as vaccines against C. pneumoniae
and other pathogens are pursued (94,95).
Conclusion
The current interest in infectious causes of atherosclero-
sis revives a venerable hypothesis. If true, the global preven-
tion and intervention opportunities could be substantial
(demonstrated with H. pylori in peptic ulcer disease). How-
ever, the seroepidemiologic data that triggered this renais-
sance lack robustness because of confounding factors (e.g.,
socioeconomic status, smoking) and publication bias towards
more positive results. Indeed, more rigorously controlled
observational and prospective studies appear to weaken the
seroepidemiologic links between infection and atherosclero-
sis. Nonetheless, studies of the vascular biology of infection
clearly demonstrate that agents such as C. pneumoniae and
CMV can elicit potentially pathogenic functions of vascular
wall cells and leukocytes in atheromata, supporting the
hypothesis that such infections may potentiate atheroscle-
rotic CVD. Results will soon be available from prospective
clinical trials that critically examine whether macrolide
antibiotic therapy reduces recurrent coronary events or mod-
ifies CHD. However, these trials will not determine eradica-
tion or suppression of one or more microbes, optimal timing
of intervention, and duration of benefits, and thus fall short
of providing convincing evidence for a causal relationship
between infectious agents and atherosclerosis. These trials
will neither define the portion of atherosclerotic CVD caused
by infection nor indicate benefits or risks of vaccine therapy.
Routine use of antibiotics to prevent atherosclerotic
events should await evidence from sufficiently powered and
well-designed clinical trials. Premature, inappropriate use
has potential adverse effects. Clearly, research on potential
infection-atherosclerosis links must continue, complemented
by a public health approach. Participants in recent work-
shops and symposia have evaluated gaps in the evidence and
outlined ways to fill them (22,23,79,96,97). All agree on the
need for more specific, sensitive, and standardized reagents
and assays (20-22).
Research must also address interactions between infec-
tion, traditional risk factors, and other determinants of host
susceptibility, such as gender and nutrition, in multifactorial
atherosclerotic CVD (7,22,79,96). It will be critical to deter-
mine the age at which pathogenesis begins and to identify
the attributable fraction of preventable or reversible disease
and the subpopulations at risk. Such data might eventually
warrant adoption of infection control strategies–minimized
exposure, vaccination, and antimicrobial therapy–aimed at
reducing the impact of symptomatic cardiovascular disease.
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